Article

Exercise training in the primary care setting reduces patients’ anxiety symptoms

Exercise training provides an effective means for reducing anxiety symptoms, with minimal risk of adverse events. Anxiety reduction is a favorable outcome of exercise interventions that were designed as a primary treatment or adjuvant for medical conditions other than anxiety.

Exercise training provides an effective means for reducing anxiety symptoms, with minimal risk of adverse events. Anxiety reduction is a favorable outcome of exercise interventions that were designed as a primary treatment or adjuvant for medical conditions other than anxiety.

Herring and colleagues examined results from 40 randomized controlled trials that studied the effects of exercise training on anxiety in sedentary, chronically ill patients. All studies had to have randomly assigned the 2914 participants to an exercise program that lasted at least 3 weeks or a comparison condition that did not involve exercise.

The patients who participated in exercise training had significantly reduced anxiety symptoms compared with the patients who remained sedentary. Programs that lasted 3 to 12 weeks reduced anxiety significantly more than programs that lasted longer than 12 weeks. The reason for the superior efficacy of the shorter programs is unclear but may be related to better adherence to treatment. The exercise sessions that lasted longer than 30 minutes relieved anxiety symptoms better than the shorter bouts.

The authors noted that exercise training may be especially useful for patients who prefer nonpharmaceutical treatments because such preferences may influence the magnitude of the treatment outcomes.

Related Videos
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
© 2024 MJH Life Sciences

All rights reserved.